Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 with or without Pertuzumab vs Trastuzumab + Taxane in HER2+ Metastatic Breast Cancer
NCT01120184Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2010
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of trastuzumab emtansine in HER2-positive metastatic breast cancer, sponsored by Roche. Started Jul 2010; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01120184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120184.